We're working with NHS England to identify and assess digitally enabled therapies that:
- follow NICE recommendations
- address a condition currently managed by the IAPT programme.
Are you the developer of a product suitable for the programme?
Have you developed a digital technology suitable for people with anxiety disorders and depression? Let us know.
What is IAPT?
Improving Access to Psychological Therapies (IAPT) services provide evidence-based psychological therapies to people with anxiety disorders and depression.
We will assess digitally enabled therapies for anxiety, depression and medically unexplained symptoms which offer the potential to expand these services further.
What is digitally enabled therapy?
Therapy content delivered online or through mobile applications which
What are we looking for?
Digital treatments that meet all of the following criteria:
- treat one of the clinical conditions covered by IAPT
- generalised anxiety disorder
- social anxiety disorder
- panic disorder
- post-traumatic stress disorder
- health anxiety (hypochondriasis)
- specific phobia
- obsessive-compulsive disorder
- body dysmorphic disorder
- irritable bowel syndrome
- chronic fatigue syndrome
- medically unexplained symptoms not otherwise specified.
- use a treatment method with content that follows our guidance
- can be delivered as part of a blended model of care, supported by an IAPT therapist
- treat adults
- have at least one randomised control trial available for the condition being assessed
- is supplied by an organisation committing to keep ownership and responsibility to maintain and update the digital therapy technology.
How do we assess the treatments?
The assessment will include:
- digital standards assessment using IAB technical questionnaire
- cost and resource impact.
The assessment outcome will be presented in an IAPT assessment briefing (IAB) to a panel of experts with clinical mental health, health economic and data analysis backgrounds. There will also be service user representation. They will use the IAB to make one of three recommendations:
- can be routed to testing in practice in IAPT services
- should not be routed to testing in practice
- needs further development.
Evaluating in practice
If your product is assessed as needing further development, you will be eligible to apply for funding to complete this work. (This is currently subject to NHS England approval - confirmation expected in summer 2017). NHS England will lead on the evaluating in practice and further development projects.
Data on the performance of digitally enabled therapies evaluated in practice will be collected. The expert panel will use this to evaluate performance. The panel will decide if the technology should be available to all IAPT services, or if further development or evaluation is required. They decide based on performance, cost and technical features of the product.
- Common mental health problems: identification and pathways to care (CG123)
- Depression in adults: recognition and management (CG90)
- Depression in adults with a chronic physical health problem: recognition and management (CG91)
- Generalised anxiety disorder and panic disorder in adults: management (CG113)
- Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)
- Post-traumatic stress disorder: management (CG26)
- Social anxiety disorder: recognition, assessment and treatment (CG159)
- Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management (CG53)
- Irritable bowel syndrome in adults: diagnosis and management (CG61)
- Antenatal and postnatal mental health: clinical management and service guidance (CG192)